sinuwave.com
Corporate | Sinuwave
http://www.sinuwave.com/about-us/corporate
Uses And Future Growth. Sinuwave Technologies Corporation is a privately owned company headquartered in Bothell, Washington. Sinuwave Technologies Corporation is dedicated to the development and commercialization of photodisinfection based technologies for the chronic rhinosinusitis market, leveraging the expertise, experience and quality management systems of its former parent, Ondine Biomedical Inc. Sinuwave is currently not for use or sale in the United States. October 7, 2013. September 5, 2013.
sinuwave.com
Chronic Rhinosinusitis (CRS) | Sinuwave
http://www.sinuwave.com/sinusitis2/chronic-sinusitis
Uses And Future Growth. Chronic sinusitis is common and debilitating. Symptoms of chronic sinusitis include severe facial pain, nasal congestion, swelling, and headaches. This can last for more than 8 weeks and can occur up to four times a year. It is estimated that more than 13 million persons in the United States live with chronic sinusitis and experience a significant impact on their quality of life. Summary of U.S. CRS Market Statistics. Sinusitis is one of the most prevalent of human diseases, secon...
sinuwave.com
How Sinuwave Works | Sinuwave
http://www.sinuwave.com/problem-solution/sinuwave-solution
Uses And Future Growth. Photodisinfection System is an Easy-to-Use Effective Technology for CRS Infections. Photodisinfection System is based on antimicrobial photodynamic therapy (aPDT), a technique relying upon activation of a well-tolerated topical photosensitizer solution via safe levels of laser light. The sensitizer, a formulation containing ultra-pure Methylene Blue (. Destroys multidrug-resistant multi-species biofilms present on the sinus mucosa;. Eliminates local exotoxins such as protease;.
sinuwave.com
The Team | Sinuwave
http://www.sinuwave.com/about-us/the-team
Uses And Future Growth. Experienced Management Team & Clinical Advisory Board. Carolyn Cross Chairman and Chief Executive Officer. Nicolas Loebel Ph.D. President and CTO. Vipul Shah VP, Finance. Roger Andersen, MD, MPH VP, Regulatory and Clinical Affairs. Dr Andersen practiced as a physician and surgeon in Seattle and directed a clinical research organization for pharmaceutical and medical device clinical trials. Prior to joining Sinuwave, Dr. Andersen worked with Ondine Biomedical for the last t...Sinuw...
sinuwave.com
Corporate | Sinuwave
http://www.sinuwave.com/about-us
Uses And Future Growth. Sinuwave Technologies Corporation is a privately owned company headquartered in Bothell, Washington. Sinuwave Technologies Corporation is dedicated to the development and commercialization of photodisinfection based technologies for the chronic rhinosinusitis market, leveraging the expertise, experience and quality management systems of its former parent, Ondine Biomedical Inc. Sinuwave is currently not for use or sale in the United States. October 7, 2013. September 5, 2013.
sinuwave.com
The CRS Problem | Sinuwave
http://www.sinuwave.com/sinusitis2/unmet-need
Uses And Future Growth. CRS Patient Population is Currently Not Adequately Treated. Bacterial biofilms have been implicated in the vast majority of chronic sinusitis cases. A biofilm is a complex community of a number of different microorganisms coexisting together and marked by the excretion of a protective and adhesive matrix called extracellular polymeric substance or exopolysaccharide. That matrix holds the biofilm together, protects the cells within it and facilitates communication among bac...
sinuwave.com
News | Sinuwave
http://www.sinuwave.com/news
Uses And Future Growth. Sinuwave Photodisinfection Abstract Presented at the American Rhinologic Society Conference. October 7, 2013. Sinuwave Photodisinfection Presenting at European Society for Photobiology 2013 Congress. September 5, 2013. Photodynamic therapy awaits its breakthrough moment. August 15, 2013. Safety & Efficacy Benefits of Sinuwave Photodisinfection Therapy to be Presented at the National American Rhinologic Society Meeting. April 19, 2012. October 7, 2013. September 5, 2013.
sinuwave.com
Sinusitis | Sinuwave
http://www.sinuwave.com/sinusitis2/sinusitis
Uses And Future Growth. Sinuwave Photodisinfection Abstract Presented at the American Rhinologic Society Conference. October 7, 2013. Sinuwave Photodisinfection Presenting at European Society for Photobiology 2013 Congress. September 5, 2013. 2016 Sinuwave Technologies Corporation Home. Sinuwave™ is currently not for use or sale in the USA.
sinuwave.com
How Sinuwave Works | Sinuwave
http://www.sinuwave.com/problem-solution
Uses And Future Growth. Photodisinfection System is an Easy-to-Use Effective Technology for CRS Infections. Photodisinfection System is based on antimicrobial photodynamic therapy (aPDT), a technique relying upon activation of a well-tolerated topical photosensitizer solution via safe levels of laser light. The sensitizer, a formulation containing ultra-pure Methylene Blue (. Destroys multidrug-resistant multi-species biofilms present on the sinus mucosa;. Eliminates local exotoxins such as protease;.
sinuwave.com
The Sinuwave Photodisinfection System | Sinuwave
http://www.sinuwave.com/problem-solution/what-is-sinuwave
Uses And Future Growth. Sinuwave is Photodisinfection for chronic sinusitis. System will treat patients with chronic sinusitis for whom medical and surgical therapies have been ineffective. The. Treatment process will be similar to existing in-office procedures currently performed by ENT specialists. Photodisinfection has demonstrated a 4 log reduction (99.99%) in bacterial load in other systems and. The reduction of pain,. The absence of drug interactions,. October 7, 2013. September 5, 2013.
SOCIAL ENGAGEMENT